Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance
Waqar Rashid, Olga Ciccarelli, Siobhan M Leary, Tarunya Arun, Anisha Doshi, Nikos Evangelou, Helen Ford, Jeremy Hobart, Saiju Jacob, Paolo A. Muraro, Katy Murray, Jacqueline Palace, Ruth Dobson
Abstract
The Association of British Neurologists last published guidelines on disease-modifying treatment (DMT) in multiple sclerosis (MS) in 2015. Since then, additional DMTs have been licensed and approved for prescribing within the National Health Service for relapsing-remitting MS, early primary progressive MS and active secondary progressive MS. This updated guidance provides a consensus-based approach to using DMTs. We provide recommendations for eligibility, starting, monitoring, switching and stopping of DMTs; pregnancy; equitable access to DMT; autologous haemopoietic stem-cell transplantation; and use of generics. We highlight best practice where it exists and discuss future priorities.